Smog Becomes a Sales Catalyst as Respiratory Drugs Surge in November
India’s deteriorating air quality has triggered a sharp rise in respiratory medicine consumption, with sales of asthma, COPD, and allergy drugs spiking strongly in November. Hospital data and pharmacy trends indicate that urban pollution levels have directly translated into increased prescriptions for bronchodilators, inhaled steroids, and anti-allergy treatments, particularly in major metro regions. Industry executives report that acute pollution episodes are now acting as short-term demand accelerators, reshaping seasonal forecasting models for respiratory drug manufacturers. The trend highlights how climate and environmental stressors are becoming structural growth drivers for chronic respiratory therapies, even as public-health costs continue to mount.
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
2026-06-26
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Betting on Next-Generation Metabolic Therapies: Pfizer’s Big Wager on Metsera and Its Strategic Reshaping in China
-
Roche Takes Natco to Supreme Court Over Generic Risdiplam Launch in India
-
India Accuses Balaji Amines of Manufacturing Pharma-Grade Propylene Glycol Without Drug Manufacturing Licence
-
Aspen Secures Approval to Market Lilly’s Mounjaro for Weight Loss in South Africa
-
Bristol Myers Squibb Launches Mavacamten (“Kopozgo”) in India for Obstructive Hypertrophic Cardiomyopathy
-
J&J to Spin Off Orthopedics Business, Raises 2025 Forecast
-
Bayer’s Ambitious Gene & Cell Therapy Pipeline Eyes Parkinson’s, Oncology, Rare Diseases
-
FDA Names Veteran Oncology Regulator Pazdur as Director of Drug Review Center
-
Pfizer Warns Germany Over Drug-Pricing Policy
-
India Raises Cancer Drug Price Caps by 50%
Recommend Reading
-
Sandoz Set to Slash Canadian Weight-loss Drug Prices by Up to 70 Percent Generics Could Expand Patient Access
-
Pfizer Lifts 2025 Profit Forecast After Q2 Earnings Beat Sales Hit $14.65 Billion Shares Jump 2.8 Percent
-
EFSA Reaffirms Safety of E948 Oxygen and E949 Hydrogen in All Foods No Health Risks Detected
-
Indian Pharma Urges US to Exempt Generics as 50 Percent Tariffs Loom National Security Probe Sparks Supply Fears
-
EFSA Confirms Safety of Vitamin E TPGS as Food Additive New Opinion Covers Multiple Use Levels
-
Brazil Raises Tomato Difenoconazole Limit 90-Fold New Pesticide Residue Standards for Key Crops Take Effect
-
Premium Global Chemical Sourcing Requests (3-7 Nov 2025)
-
Korea MFDS Proposes Major Edits to Imported Food Hygiene Rules Deadline for Public Comments Set for August 20
-
Vendor Shipment Surge Halts Mid-October PC Price Increase
-
Change Rate Remains Positive, This Round of Refined Oil Retail Prices in China Is About to Increase